1. |
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med, 2011, 365(23): 2205-2219.
|
2. |
Firestein GS. Evolving concepts of rheumatoid arthritis. Nature, 2003, 423(6937): 356-361.
|
3. |
中华医学会风湿病学分会. 2018中国类风湿关节炎诊疗指南. 中华内科杂志, 2018, 57(4): 242-251.
|
4. |
Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov, 2003, 2(6): 473-488.
|
5. |
Hu H, Luan L, Yang K, et al. Burden of rheumatoid arthritis from a societal perspective: a prevalence-based study on cost of this illness for patients in China. Int J Rheum Dis, 2018, 21(8): 1572-1580.
|
6. |
史方, 傅华, 卢伟, 等. 上海市关节炎疾病负担评价. 上海: 复旦大学, 2005.
|
7. |
Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc, 1949, 140(8): 659-662.
|
8. |
曾小峰, 朱松林, 谭爱春, 等. 我国类风湿关节炎疾病负担和生存质量研究的系统评价. 中国循证医学杂志, 2013, 13(3): 300-307.
|
9. |
Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm, 2003, 9(1): 53-61.
|
10. |
Brennan A, Bansback N, Reynolds A, et al. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford), 2004, 43(1): 62-72.
|
11. |
Soini EJ, Hallinen TA, Puolakka K, et al. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ, 2012, 15(2): 340-351.
|
12. |
Diamantopoulos A, Benucci M, Capri S, et al. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ, 2012, 15(3): 576-585.
|
13. |
Diamantopoulos A, Finckh A, Huizinga T, et al. Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK. Pharmacoeconomics, 2014, 32(8): 775-787.
|
14. |
Athanasakis K, Tarantilis F, Tsalapati K, et al. Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece. Rheumatol Int, 2015, 35(9): 1489-1495.
|
15. |
Carlson JJ, Ogale S, Dejonckheere F, et al. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis. Value Health, 2015, 18(2): 173-179.
|
16. |
Hidalgo-Vega Á, Villoro R, Blasco JA, et al. Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain. Cost Eff Resour Alloc, 2015, 13: 11.
|
17. |
Lee MY, Park SK, Park SY, et al. Cost-effectiveness of tofacitinib in the treatment of moderate to severe rheumatoid arthritis in South Korea. Clin Ther, 2015, 37(8): 1662-1676.
|
18. |
Tanaka E, Inoue E, Hoshi D, et al. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. Mod Rheumatol, 2015, 25(4): 503-513.
|
19. |
Hashemi-Meshkini A, Nikfar S, Glaser E, et al. Cost-effectiveness analysis of tocilizumab in comparison with infliximab in iranian rheumatoid arthritis patients with inadequate response to tDMARDs: a multistage markov model. Value Health Reg Issues, 2016, 9: 42-48.
|
20. |
Park SK, Park SH, Lee MY, et al. Cost-effectiveness analysis of treatment sequence initiating with etanercept compared with leflunomide in rheumatoid arthritis: impact of reduced etanercept cost with patent expiration in South Korea. Clin Ther, 2016, 38(11): 2430-2446.
|
21. |
Jansen JP, Incerti D, Mutebi A, et al. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. J Med Econ, 2017, 20(7): 703-714.
|
22. |
Tzanetakos C, Tzioufas A, Goules A, et al. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece. Rheumatol Int, 2017, 37(9): 1441-1452.
|
23. |
Alemao E, Johal S, Al MJ, et al. Cost-Effectiveness analysis of abatacept compared with adalimumab on background methotrexate in biologic-naive adult patients with rheumatoid arthritis and poor prognosis. Value Health, 2018, 21(2): 193-202.
|
24. |
Claxton L, Taylor M, Gerber RA, et al. Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States. Curr Med Res Opin, 2018, 34(11): 1991-2000.
|
25. |
Whittington MD, McQueen RB, Ollendorf DA, et al. Assessing the value of sarilumab monotherapy for adults with moderately to severely active rheumatoid arthritis: a cost-effectiveness analysis. J Manag Care Spec Pharm, 2019, 25(1): 80-87.
|
26. |
Launois R, Avouac B, Berenbaum F, et al. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol, 2011, 38(5): 835-845.
|